Boehringer Ingelheim and Eli Lilly said they are collaborating in a new clinical trial to evaluate empagliflozin in patients with chronic kidney disease.
“Our plans for this new trial are yet another example of our ongoing commitment to improving patient health, especially in areas where unmet needs exist,” Boehringer Ingelheim Global Vice President Medicine Professor Hans-Juergen Woerle said in a release. “We look forward to exploring the potential that empagliflozin may offer for people with chronic kidney disease.”
The trial will enroll approximately 5,000 participants to evaluate empagliflozin in treating chronic kidney disease. The participants will include those with and without Type 2 diabetes.
A previous trial, EMPA-REG OUTCOME, evaluated empagliflozin when added to standard medications for Type 2 diabetes and cardiovascular disease and found that it reduced the risk of cardiovascular death by 38 percent when compared to a placebo. The trial also found that empagliflozin reduced the risk of new or worsening kidney disease by 39 percent versus the placebo.
“Based on the cardiovascular and renal results of the EMPA-REG OUTCOME trial, we along with Boehringer Ingelheim look forward to starting this new trial to gather evidence in support of a potential new indication for empagliflozin in people with chronic kidney disease," Lilly Diabetes Product Development Vice President Jeff Emmick said in the release.
